Week-24 safety of fostemsavir in heavily treatment-experienced participants with HIV-1 (Study 205888, formerly AI438-047)

被引：0
|
作者：
Kozal, M. [1 ]
Aberg, J. [2 ]
Pialoux, G. [3 ]
Cahn, P. [4 ]
Thompson, M. [5 ]
Molina, J-M [6 ]
Grinsztejn, B. [7 ]
Diaz, R. [8 ]
Lazzarin, A. [9 ]
Gummel, M. [10 ]
Pierce, A. [11 ]
Ackerman, P. [12 ]
Llamoso, C. [12 ]
Lataillade, M. [12 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Hop Tenon, Paris, France
[4] Fdn Huesped, Buenos Aires, DF, Argentina
[5] AIDS Res Consortium Atlanta, Atlanta, GA USA
[6] Hop St Louis, Paris, France
[7] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil
[8] Univ Fed Sao Paulo, Sao Paulo, Brazil
[9] Osped San Raffaele, Milan, Italy
[10] GlaxoSmithKline, Upper Providence, PA USA
[11] ViiV Healthcare, Res Triangle Pk, NC USA
[12] ViiV Healthcare, Branford, CT USA
来源：
HIV MEDICINE | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P31
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [41] Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study
    Gathe, Joseph C.
    Hardwicke, Robin L.
    Garcia, Fernando
    Weinheimer, Steven
    Lewis, Stanley T.
    Cash, Robert Brandon
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 86 (04) : 482 - 489
  • [42] Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2
    Hardy, W. David
    Gulick, Roy M.
    Mayer, Howard
    Faetkenheuer, Gerd
    Nelson, Mark
    Heera, Jayvant
    Rajicic, Natasa
    Goodrich, James
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (05) : 558 - 564
  • [43] Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection
    Montaner, Julio
    Yeni, Patrick
    Clumeck, Nathan N.
    Faetkenheuer, Gerd
    Gatell, Jose
    Hay, Phillip
    Seminari, Elena
    Peeters, Monika P.
    Schoeller-Gyuere, Monika
    Simonts, Myriam
    Woodfall, Brian
    CLINICAL INFECTIOUS DISEASES, 2008, 47 (07) : 969 - 978
  • [44] A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week Results
    Elion, Richard
    Molina, Jean-Michel
    Lopez, Jose Ramn Arribas
    Cooper, David
    Maggiolo, Franco
    Wilkins, Edmund
    Conway, Brian
    Liu, Ya-Pei
    Margot, Nicolas
    Rhee, Martin
    Chuck, Steven L.
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (04) : 494 - 497
  • [45] Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use:: Data from a prospective, observational, multicenter study
    Moreno, Santiago
    Domingo, Pere
    Palacios, Rosario
    Santos, Jesus
    Falco, Vicenc
    Murillas, Javier
    Estrada, Vicente
    Ena, Javier
    Alvarez, Maria Luisa
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 42 (03) : 385 - 387
  • [46] Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
    Madruga, Jose Valdez
    Cahn, Pedro
    Grinsztejn, Beatriz
    Haubrich, Richard
    Lalezari, Jacob
    Mills, Anthony
    Pialoux, Gilles
    Wilkin, Timothy
    Peeters, Monika
    Vingerhoets, Johan
    de Smedt, Goedele
    Leopold, Lorant
    Trefiglio, Roberto
    Woodfall, Brion
    LANCET, 2007, 370 (9581): : 29 - 38
  • [47] Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials (vol 369, pg 1169, 2007)
    Clotet, B.
    Bellos, N.
    Molina, J. -M
    LANCET, 2008, 371 (9607): : 116 - 116
  • [48] Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
    Lazzarin, Adriano
    Campbell, Thomas
    Clotet, Bonaventura
    Johnson, Margaret
    Katlama, Christine
    Moll, Arend
    Towner, William
    Trortier, Benoit
    Peeters, Monika
    Vingerhoets, Johan
    de Smedt, Goedele
    Baeten, Benny
    Beets, Greet
    Sinha, Rekha
    Woodfall, Brian
    LANCET, 2007, 370 (9581): : 39 - 48
  • [49] Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
    Molina, Jean-Michel
    LaMarca, Anthony
    Andrade-Villanueva, Jaime
    Clotet, Bonaventura
    Clumeck, Nathan
    Liu, Ya-Pei
    Zhong, Lijie
    Margot, Nicolas
    Cheng, Andrew K.
    Chuck, Steven L.
    LANCET INFECTIOUS DISEASES, 2012, 12 (01): : 27 - 35
  • [50] Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF in treatment-experienced HIV-1 infected patients: 12-month results from the German TAFNES cohort study
    Hillenbrand, H.
    Knechten, H.
    Kuemmerle, T.
    Scholten, S.
    Schuebel, N.
    Haubrich, R.
    Heinzkill, M.
    Goerner, K.
    Stellbrink, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
12345